Alzheon, Inc.

Alzheon is a clinical-stage biopharmaceutical company developing small-molecule treatments for neurodegenerative disorders, with a Phase 3 program for Alzheimer's disease based on an anti-aggregation mechanism. The company's lead program, valiltramiprosate (ALZ-801), is an oral anti-amyloid oligomer inhibitor being tested in early Alzheimer's disease and mild cognitive impairment, while a second clinical-stage program (ALZ-507) targets Alzheimer's disease prevention.